Lymphoma

realMIND: Observational Study on safety and effectiveness of tafasitamab in combination with lenalidomide in Patients With Relapsed or Refractory DLBCL

Incyte Study ID:
MOR208C414
CT.gov ID:
NCT04981795
Eudra ID:
N/A
Sponsor:
Incyte Corporation
Collaborator:
N/A
Study Contact Information:
1.855.463.3463 or [email protected]
Recruiting
Subscribe to UpdatesContact Us

Clinical Study Purpose

The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.

Clinical Study Summary

MEDICAL CONDITION(S)
  • Lymphoma
    • PRODUCT
  • Drug: Tafasitamab
    • COLLABORATORS
    N/A
    DATE
    Sep 2021 - Oct 2025
    TYPE
    Observational
    PHASE
    N/A
    SEX
    Female & Male
    AGE
    18+ years
    ACCEPTS HEALTHY VOLUNTEERS
    No

    Clinical Study Locations

    Location
    Status
    Location
    Alabama Oncology
    Birmingham, Alabama, US, 35211
    Status
    Recruiting
    Location
    Clearview Cancer Institute
    Huntsville, Alabama, US, 35805
    Status
    Recruiting
    Location
    McFarland Clinic P.C.
    Ames, Iowa, US, 50010
    Status
    Recruiting
    Location
    Tulane Cancer Center
    New Orleans, Louisiana, US, 70112
    Status
    Completed
    Location
    American Oncology Partners of Maryland PA
    Bethesda, Maryland, US, 20817
    Status
    Recruiting
    Location
    Henry Ford Health System
    Detroit, Michigan, US, 48202
    Status
    Recruiting

    Key Inclusion and Exclusion Criteria

    Inclusion Criteria

    • 1) Age ≥18 years at the time of diagnosis of R/R DLBCL
    • 2) Initiated or initiating tafasitamab treatment

    Exclusion Criteria

    • Initiated or initiating tafasitamab treatment in the context of an interventional study.

    Protocol Summary

    Incyte Study ID:
    MOR208C414
    Primary Purpose:
    N/A
    Allocation:
    N/A
    Study Design:
    N/A
    Masking:
    N/A
    Interventions:
    Drug
    Enrollment:
    100
    Primary Outcome
    Open

    Treatment Patterns - Safety

    Timeframe: 2 Years

    Treatment Patterns - Effectiveness (a)

    Timeframe: 2 Years

    Treatment Patterns - Effectiveness (b)

    Timeframe: 2 Years

    Treatment Patterns - Effectiveness (c)

    Timeframe: 2 Years

    Treatment Patterns - Effectiveness (d)

    Timeframe: 2 Years

    Treatment Patterns - Effectiveness (e)

    Timeframe: 2 Years

    Treatment Patterns - Effectiveness (f)

    Timeframe: 2 Years

    Secondary Outcome
    Open

    Physician-reported clinical outcome (a)

    Timeframe: 2 Years

    Physician-reported clinical outcome (b)

    Timeframe: 2 Years

    Physician-reported clinical outcome (c)

    Timeframe: 2 Years

    Physician-reported clinical outcome (d)

    Timeframe: 2 Years

    Physician-reported clinical outcome (e)

    Timeframe: 2 Years

    Physician-reported clinical outcome (f)

    Timeframe: 2 Years